PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 505
- 主要终点
- Breast cancer-free interval for patients with PIK3CA-mutated tumors
研究概览
简要总结
This research trial studies phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation analysis in tissue samples from older patients with stage I breast cancer. Studying samples of tissue from patients with stage I breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
详细描述
PRIMARY OBJECTIVES:
To assess the relapse free-survival difference between patients with PIK3CA mutated and wild-type (WT) tumors and therefore validate PIK3CA mutation status as an important biomarker in women 70 years or older diagnosed with breast cancer.
OUTLINE:
Previously collected tissue samples are analyzed via mutation analysis of PIK3CA.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Breast cancer-free interval for patients with PIK3CA-mutated tumors
时间窗: baseline
Tumor size
时间窗: baseline
Estrogen receptor status
时间窗: baseline
Lymph node status
时间窗: baseline
Treatment group associated with PIK3CA expression
时间窗: baseline
次要结局
- Overall survival associated with PIK3CA(baseline)
- Breast cancer specific survival associated with PIK3CA expression(baseline)